Gami Apoor S, Witt Brandi J, Howard Daniel E, Erwin Patricia J, Gami Lisa A, Somers Virend K, Montori Victor M
Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14. doi: 10.1016/j.jacc.2006.09.032. Epub 2007 Jan 12.
The purpose of this research was to assess the association between the metabolic syndrome (MetSyn) and cardiovascular events and mortality by meta-analyses of longitudinal studies.
Controversy exists regarding the cardiovascular risk associated with MetSyn.
We searched electronic reference databases through March 2005, studies that referenced Reaven's seminal article, abstracts presented at meetings in 2003 to 2004, and queried experts. Two reviewers independently assessed eligibility. Longitudinal studies reporting associations between MetSyn and cardiovascular events or mortality were eligible. Two reviewers independently used a standardized form to collect data from published reports. Authors were contacted. Study quality was assessed by the control of selection, detection, and attrition biases.
We found 37 eligible studies that included 43 cohorts (inception 1971 to 1997) and 172,573 individuals. Random effects meta-analyses showed MetSyn had a relative risk (RR) of cardiovascular events and death of 1.78 (95% confidence interval [CI] 1.58 to 2.00). The association was stronger in women (RR 2.63 vs. 1.98, p = 0.09), in studies enrolling lower risk (<10%) individuals (RR 1.96 vs. 1.43, p = 0.04), and in studies using factor analysis or the World Health Organization definition (RR 2.68 and 2.06 vs. 1.67 for National Cholesterol Education Program definition and 1.35 for other definitions; p = 0.005). The association remained after adjusting for traditional cardiovascular risk factors (RR 1.54, 95% CI 1.32 to 1.79).
The best available evidence suggests that people with MetSyn are at increased risk of cardiovascular events. These results can help clinicians counsel patients to consider lifestyle interventions, and should fuel research of other preventive interventions.
本研究旨在通过对纵向研究的荟萃分析,评估代谢综合征(MetSyn)与心血管事件及死亡率之间的关联。
关于与MetSyn相关的心血管风险存在争议。
我们检索了截至2005年3月的电子参考文献数据库、引用雷文开创性文章的研究、2003年至2004年会议上发表的摘要,并咨询了专家。两名评审员独立评估研究的合格性。报告MetSyn与心血管事件或死亡率之间关联的纵向研究符合要求。两名评审员独立使用标准化表格从已发表的报告中收集数据。与作者进行了联系。通过控制选择、检测和失访偏倚来评估研究质量。
我们发现37项符合要求的研究,包括43个队列(起始时间为1971年至1997年)和172,573名个体。随机效应荟萃分析显示,MetSyn发生心血管事件和死亡的相对风险(RR)为1.78(95%置信区间[CI]为1.58至2.00)。在女性中该关联更强(RR为2.63,而男性为1.98,p = 0.09),在纳入低风险(<10%)个体的研究中(RR为1.96,而其他研究为1.43,p = 0.04),以及在使用因子分析或世界卫生组织定义的研究中(RR分别为2.68和2.06,而采用国家胆固醇教育计划定义的RR为1.67,其他定义的RR为1.35;p = 0.005)。在调整了传统心血管危险因素后,该关联仍然存在(RR为1.54,95% CI为1.32至1.79)。
现有最佳证据表明,患有MetSyn的人发生心血管事件的风险增加。这些结果可帮助临床医生为患者提供咨询,使其考虑生活方式干预措施,并应推动对其他预防性干预措施的研究。